Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faecal calprotectin-guided anti-TNF de-escalation in adolescents and young adults with inflammatory bowel disease
NL-OMON52654Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab and infliximab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by University Medical Center Groningen. Started Mar 2021; status: recruiting.
02
Drugs
adalimumabinfliximab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON52654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52654.